- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01324258
Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
GSK1120212 has demonstrated anti-proliferative activity against a broad range of tumors cell lines and xenograft models. To date, MEK inhibitors have demonstrated evidence of both pharmacodynamic and clinical activity in early trials.
This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This study is designed to identify recommended doses and regimens in Japanese subjects for the future development of GSK1120212.
This study will be conducted in subject with solid tumors, and GSK1120212 single agent treatment to assess safety, tolerability, PK and efficacy (Part 1) and combination treatment with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which gemcitabine has been approved in 4-week schedule to assess safety, tolerability, PK and efficacy(Part 2) will be conducted in the same protocol.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Osaka, Giappone, 589-8511
- GSK Investigational Site
-
Tokyo, Giappone, 181-8611
- GSK Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Correspond Part 1 (Single agent) and Part 2 (Combination)
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- Age 20 years old or older at consent given
- Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
- Negative for hepatitis B surface (HBs) antigen, hepatitis virus Bc (HBc) antibody, and HBs antibody. HBs antigen-negative subjects who test positive for both HBc antibody and HBs antibody or either of them may be eligible when their HBV DNA quantification result is negative
- Negative HCV antibody test
- Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of the first dose of GSK1120212 until 16 weeks after the last dose of GSK1120212
- A female subject is eligible to participate if she is of;Non-childbearing potential females or female subjects with child-bearing potential must agree to use contraception until four weeks after the last dose of GSK1120212 to sufficiently minimize the risk of pregnancy at that point
Part 1 -Dose escalation single agent part
- Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy. Subjects with primary brain tumor are excluded
- Adequate organ system functions as defined below; Absolute neutrophil count≥1,200/uL Hemoglobin≥9g/dL Platelets≥75,000/uL PT/INR and APTT≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA
Part 2 -Combination part
- Tumor type criteria;Histologically or cytologically confirmed diagnosis of solid tumor malignancy. Eligible are the cancers for which gemcitabine has been approved in 4-week schedule;1,000mg/m2 weekly for 3weeks followed by 1 week rest at the 4th week, including non-small cell lung cancer, pancreatic cancer, biliary cancer, and urothelial cancer, to which gemcitabine monotherapy is considered to be appropriate
- Adequate organ system functions as defined below; Absolute neutrophil count≥1,500/uL Hemoglobin≥9g/dL Platelets≥100,000/uL PT/INR and APTT1≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA
Exclusion Criteria:
Correspond Part 1 (Single agent) and Part 2 (Combination)
- Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures
- Use of an investigational anti-cancer drug within 28 days or five half-lives, whichever is shorter preceding the first dose of GSK1120212. Or use of an other investigational drug within 28 days or five half-lives, whichever is longer preceding the first dose of GSK1120212
- Previous treatment with a MEK inhibitor
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or subinvestigator, contraindicates their participation
- History of interstitial lung disease or pneumonitis
- Current use of a prohibited medication
- Any major surgery, radiotherapy, or immunotherapy within 21 days before initiation of GSK1120212. Or chemotherapy regimens with delayed toxicity within 21 days before initiation of GSK1120212. Or chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the two weeks before initiation of GSK1120212
- History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
- QTc B≥480 msecs
- History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks
- History or evidence of current≥Class II congestive heart failure as defined by New York Heart Association
- History or evidence of current clinically significant uncontrolled arrhythmias
- History of HIV infection
- Evidence of severe or uncontrolled systemic diseases
- Unresolved toxicity greater than CTCAE (Version 3.0) Grade 1 from previous anti-cancer therapy except alopecia
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO)
- Pregnant or lactating female
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
- Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol
- Unwillingness or inability to follow the procedures outlined in the protocol
Part 1 -Dose escalation single agent part
- History of another malignancy
- Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs
Part 2 -Combination part
- History of another malignancy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: GSK1120212
Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
|
Part1 and Part2
Part2
|
Sperimentale: GSK1120212+Gemcitabine
Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
|
Part2
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Number of participants with adverse events as a measure of safety and tolerability
Lasso di tempo: Until a subject has a Dose Limiting Toxicity, withdraws from the study or dies
|
Until a subject has a Dose Limiting Toxicity, withdraws from the study or dies
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax etc.) values for GSK1120212
Lasso di tempo: Cycle0, Cycle1 Day1,8,15,22, Cycle2 Day1 in Part 1
|
Individual subject parameter values as well as a descriptive summary (mean, standard deviation, median, minimum, maximum, geometric mean, and the standard deviation, CV% and 95% confidence interval of log-transformed parameters) by dose cohort will be reported.
|
Cycle0, Cycle1 Day1,8,15,22, Cycle2 Day1 in Part 1
|
To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax, etc.) values for GSK1120212 and Gemcitabine
Lasso di tempo: Cycle1 Day15 in Part2
|
Individual subject parameter values as well as a descriptive summary (mean, standard deviation, median, minimum, maximum, geometric mean, and the standard deviation, CV% and 95% confidence interval of log-transformed parameters) by dose cohort will be reported.
|
Cycle1 Day15 in Part2
|
Number of participants with the indicated tumor response defined by RECIST v1.1
Lasso di tempo: Every eight weeks during the study
|
Every eight weeks during the study
|
|
Serum level of cyctokines
Lasso di tempo: Cycle1 Day15 in Part1 and Part2
|
Cycle1 Day15 in Part1 and Part2
|
|
Tissue level of expression of the indicated protein including pERK and Ki67 if possible
Lasso di tempo: Cycle1 Day15 in Part1 and Part2
|
Cycle1 Day15 in Part1 and Part2
|
|
Tissue level of gene mutation including BRAF and KRAS if possible
Lasso di tempo: Cycle1 Day15 in Part1 and Part2
|
Cycle1 Day15 in Part1 and Part2
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Inibitori enzimatici
- Antimetaboliti, Antineoplastici
- Antimetaboliti
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Inibitori della chinasi proteica
- Gemcitabina
- Trametinib
Altri numeri di identificazione dello studio
- 114784
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Tumori solidi
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su GSK1120212
-
Novartis PharmaceuticalsTerminatoCancroFrancia, Stati Uniti, Olanda, Canada, Taiwan, Corea, Repubblica di
-
National Cancer Institute (NCI)Attivo, non reclutanteNeoplasia solida maligna avanzata | Neoplasia solida maligna metastatica | Neoplasia maligna metastatica nel fegato | Neoplasia solida non resecabileStati Uniti, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupAttivo, non reclutanteLeucemia mielomonocitica giovanile | Neurofibromatosi di tipo 1Stati Uniti
-
National Cancer Institute (NCI)CompletatoEmangioendotelioma epitelioide localmente avanzato | Emangioendotelioma epitelioide metastatico | Emangioendotelioma epitelioide non resecabileStati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis; Stand Up To Cancer; Prostate Cancer FoundationAttivo, non reclutanteCarcinoma prostatico metastatico | Carcinoma prostatico ricorrente | Cancro alla prostata in stadio IV | Cancro alla prostata resistente agli ormoniStati Uniti
-
National Cancer Institute (NCI)CompletatoMieloma plasmacellulare refrattario | Mieloma plasmacellulare ricorrenteCanada
-
National Cancer Institute (NCI)CompletatoMelanoma uveale in stadio IV AJCC v7 | Melanoma Uveale RicorrenteStati Uniti, Francia, Regno Unito
-
National Cancer Institute (NCI)GlaxoSmithKlineCompletatoCancro al seno in stadio IV | Carcinoma mammario ricorrente | Carcinoma mammario invasivo | Recettore per gli estrogeni negativo | HER2/Neu negativo | Recettore del progesterone negativo | Carcinoma mammario triplo negativoStati Uniti
-
City of Hope Medical CenterNational Cancer Institute (NCI)ReclutamentoCarcinoma anaplastico della ghiandola tiroidea | Mutazione BRAF V600K presente | BRAF NP_004324.2:p.V600EStati Uniti
-
University of California, DavisNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; NovartisAttivo, non reclutanteMutazione del gene KRAS | Carcinoma polmonare non a piccole cellule in stadio IV AJCC v7 | Carcinoma polmonare non a piccole cellule non squamoso ricorrente | Carcinoma polmonare metastatico non squamoso non a piccole celluleStati Uniti